This antibody is purified through a protein A column, followed by peptide affinity purification.
Immunogène
This COP1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 37-65 amino acids from the N-terminal region of human COP1.
RFWD2
Reactivité: Humain
WB, ELISA
Hôte: Lapin
Polyclonal
unconjugated
Indications d'application
For FACS starting dilution is: 1:10~50
For WB starting dilution is: 1:1000
Restrictions
For Research Use only
Format
Liquid
Concentration
0.35 mg/mL
Buffer
Supplied in PBS with 0.09 % (W/V) sodium azide.
Agent conservateur
Sodium azide
Précaution d'utilisation
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Stock
4 °C,-20 °C
Stockage commentaire
Store at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Antigène
RFWD2
(Ring Finger and WD Repeat Domain 2, E3 Ubiquitin Protein Ligase (RFWD2))
anticorps COP1, anticorps RNF200, anticorps AI316802, anticorps C80879, anticorps Cop1, anticorps RGD1304773, anticorps RFWD2, anticorps cop1, anticorps rnf200, anticorps zgc:163067, anticorps ring finger and WD repeat domain 2, anticorps ring finger and WD repeat domain 2, E3 ubiquitin protein ligase, anticorps ring finger and WD repeat domain 2, E3 ubiquitin protein ligase L homeolog, anticorps RFWD2, anticorps Rfwd2, anticorps rfwd2, anticorps rfwd2.L
Sujet
Caspase inhibitor. Acts as a regulator of procaspase-1/CASP1 activation implicated in the regulation of the proteolytic maturation of pro-interleukin-1 beta (IL1B) and its release during inflammation. Inhibits the release of IL1B in response to LPS in monocytes. Also induces NF-kappa-B activation during the pro-inflammatory cytokine response. Also able to inhibit CASP1-mediated neuronal cell death, TNF-alpha, hypoxia-, UV-, and staurosporine-mediated cell death but not ER stress-mediated cell death. Acts by preventing activation of caspases CASP1 and CASP4, possibly by preventing the interaction between CASP1 and RIPK2.